Top 10 Companies in the (R)-3‑Amino‑3‑phenylpropanoic Acid (CAS 13921‑90‑9) Market (2026): Market Leaders Driving Global Pharmaceutical Innovation

MARKET INSIGHTS

Global (R)-3-Amino-3-phenylpropanoic acid (CAS 13921‑90‑9) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 6.5% during the forecast period.

(R)-3-Amino-3-phenylpropanoic acid (CAS 13921‑90‑9) is a chiral beta‑amino acid derivative characterized by its (R)-configuration at the amino‑bearing carbon centre. It serves as a critical building block in asymmetric synthesis and pharmaceutical manufacturing, particularly in the development of peptidomimetics, chiral ligands, and active pharmaceutical ingredients (APIs). Its structural versatility makes it highly valuable across medicinal chemistry and fine chemical research applications.

The market is witnessing steady growth driven by rising demand for enantiopure intermediates in drug discovery, expanding pharmaceutical R&D pipelines, and growing adoption of chiral synthesis methodologies. Furthermore, increasing investments in peptide‑based therapeutics and the broader fine chemicals sector are reinforcing demand. Key suppliers operating in this space include Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Combi‑Blocks, among other specialty chemical manufacturers maintaining global distribution networks.

(R)-3‑Amino‑3‑phenylpropanoic Acid (CAS 13921‑90‑9) Market – View in Detailed Research Report

Market Size

In 2025, the compound’s value reached USD 28.4 million, with a forecasted rise to USD 52.7 million by 2034. The upward trajectory reflects the compound’s integral role in modern drug development and the growing emphasis on stereochemical precision.

Product Definition

As a chiral beta‑amino acid, (R)-3‑Amino‑3‑phenylpropanoic acid is employed as an intermediate for synthesising peptidomimetics, enzyme inhibitors, and complex APIs. Its (R)-configuration ensures high selectivity in reactions, making it indispensable for pharmaceutical intermediates that require stringent purity standards.

Top 10 Companies

1. MilliporeSigma

   Headquarters: Darmstadt, Germany
   Key Offering: Pharmaceutical‑grade (R)-3‑Amino‑3‑phenylpropanoic acid, custom synthesis services

   MilliporeSigma leverages its extensive enzymatic resolution platform to deliver high‑purity intermediates for large‑scale API production. Its global network supports rapid turnaround for contract development and manufacturing organisations.

   Sustainability & Growth Initiatives:

   • Investment in biocatalytic processes to reduce solvent use
   • Expansion of cGMP facilities in North America
   • Partnerships with academic institutions for novel chiral catalysts

2. Merck KGaA (Sigma‑Aldrich)

   Headquarters: Darmstadt, Germany
   Key Offering: High‑purity (R)-3‑Amino‑3‑phenylpropanoic acid, supply chain optimisation solutions

   Merck’s integrated platform combines proprietary enzymatic resolution with advanced analytics, ensuring consistent enantiomeric excess for critical drug intermediates.

   Sustainability & Growth Initiatives:

   • Adoption of continuous flow synthesis to cut waste
   • Commitment to reduce CO₂ footprint by 20 % by 2030
   • Strategic alliances with biotech hubs in Asia‑Pacific

3. Tokyo Chemical Industry (TCI)

   Headquarters: Tokyo, Japan
   Key Offering: Enantiomerically pure (R)-3‑Amino‑3‑phenylpropanoic acid, custom synthesis

   TCI’s focus on asymmetric catalysis has positioned it as a preferred supplier for peptide‑based drug development in Japan and beyond.

   Sustainability & Growth Initiatives:

   • Development of green solvent systems
   • Expansion of production capacity in Southeast Asia
   • Collaboration with pharma R&D teams on novel chiral ligands

4. Biosynth Carbosynth

   Headquarters: Basel, Switzerland
   Key Offering: Custom synthesis of (R)-3‑Amino‑3‑phenylpropanoic acid, API intermediates

   Biosynth’s niche expertise in small‑batch, high‑purity production serves academic and early‑stage biotech companies.

   Sustainability & Growth Initiatives:

   • Implementation of closed‑loop solvent recovery
   • Investment in biocatalyst development
   • Expansion of service offerings into agrochemical intermediates

5. Enamine Ltd.

   Headquarters: Kyiv, Ukraine
   Key Offering: High‑purity (R)-3‑Amino‑3‑phenylpropanoic acid, custom synthesis

   Enamine’s rapid‑turnaround synthesis platform supports global pharma and CDMO clients seeking flexible supply.

   Sustainability & Growth Initiatives:

   • Adoption of renewable energy sources for production
   • Development of scalable enzymatic processes
   • Partnerships with European pharma for joint R&D

6. Pharmablock Sciences

   Headquarters: Shenzhen, China
   Key Offering: Enantiomerically pure (R)-3‑Amino‑3‑phenylpropanoic acid, cGMP manufacturing

   Pharmablock’s rapid scale‑up capability addresses the growing demand for peptide therapeutics in the Asian market.

   Sustainability & Growth Initiatives:

   • Investment in green chemistry initiatives
   • Expansion of production lines to meet 2028 capacity targets
   • Collaboration with Chinese biotech firms on novel drug candidates

7. Hairui Chemical

   Headquarters: Shanghai, China
   Key Offering: (R)-3‑Amino‑3‑phenylpropanoic acid, custom synthesis, API intermediates

   Hairui’s focus on cost‑effective production supports generic drug developers and CDMOs.

   Sustainability & Growth Initiatives:

   • Implementation of energy‑efficient reactors
   • Development of scalable biocatalytic routes
   • Partnerships with local universities for talent development

8. Combi‑Blocks Inc.

   Headquarters: San Diego, USA
   Key Offering: (R)-3‑Amino‑3‑phenylpropanoic acid, custom synthesis, API intermediates

   Combi‑Blocks offers rapid, small‑batch production tailored to niche research and early‑stage drug discovery.

   Sustainability & Growth Initiatives:

   • Adoption of micro‑reactor technology to reduce waste
   • Expansion of service portfolio to include chiral ligands
   • Collaboration with biotech incubators for product development

9. Oakwood Chemical

   Headquarters: Houston, USA
   Key Offering: (R)-3‑Amino‑3‑phenylpropanoic acid, large‑scale production, API intermediates

   Oakwood’s high‑capacity facilities support global pharma clients with stringent purity requirements.

   Sustainability & Growth Initiatives:

   • Implementation of renewable energy in production plants
   • Continuous improvement of solvent recovery processes
   • Strategic alliances with CDMOs in North America

10. Sigma‑Aldrich (Merck)

    Headquarters: Milwaukee, USA
    Key Offering: High‑purity (R)-3‑Amino‑3‑phenylpropanoic acid, research and industrial grades

    Sigma‑Aldrich’s extensive distribution network ensures rapid access for research labs and commercial manufacturers alike.

    Sustainability & Growth Initiatives:

    • Reduction of hazardous solvent usage across product lines
    • Expansion of sustainable packaging solutions
    • Investment in green chemistry research programmes

Download FREE Sample Report

Get Full Report

Outlook (2026‑2034)

The next decade will see continued momentum as the compound’s role in peptide‑based therapeutics expands. Regulatory approvals for new chiral APIs, coupled with the adoption of continuous flow chemistry, will drive demand. Supply chain resilience initiatives and investment in biocatalytic platforms are expected to keep production costs in check while maintaining high purity standards.

Future Trends

• Expansion of peptide‑based drug pipelines, especially in oncology and neurology
• Increased use of flow‑chemistry and continuous manufacturing for cost efficiency
• Growing emphasis on sustainability, with greener solvents and energy‑efficient processes
• Digitalisation of supply‑chain management to enhance traceability and compliance
• Rising demand for ultra‑high‑purity (≥99.5 %) grades to meet tightening regulatory thresholds